Search Results
You are looking at 11 - 20 of 136 items for :
- Abstract: Hypoparathyroidism x
- Abstract: Osteo* x
- Abstract: Vitamin D x
Centre de Référence des Maladies Rares du Calcium et du Phosphore Filière de Santé Maladies Rares OSCAR, Paris, France
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, INSERM, UMRS1138, Paris, France
Search for other papers by Jean-Philippe Bertocchio in
Google Scholar
PubMed
Search for other papers by Natalie Grosset in
Google Scholar
PubMed
Search for other papers by Lionel Groussin in
Google Scholar
PubMed
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
Search for other papers by Fabrice Larceneux in
Google Scholar
PubMed
Search for other papers by Anne Lienhardt-Roussie in
Google Scholar
PubMed
Université Paris-Saclay, Inserm U1185, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Service d’Endocrinologie et Diabète de l’Enfant, Centre de Référence des Maladies Rares du Calcium et du Phosphore et Filière de Santé Maladies Rares OSCAR, Hôpital Bicêtre Paris Saclay, Le Kremlin-Bicêtre, France
Search for other papers by Agnès Linglart in
Google Scholar
PubMed
Centre de Référence des Maladies Rares du Calcium et du Phosphore Filière de Santé Maladies Rares OSCAR, Paris, France
Assistance Publique-Hôpitaux de Paris, Institut Necker-Enfants Malades, INSERM U1151 – CNRS UMR 8253, Paris, France
Search for other papers by Gérard Maruani in
Google Scholar
PubMed
Association Francophone de Chirurgie Endocrinienne (AFCE), France
Search for other papers by Eric Mirallie in
Google Scholar
PubMed
Search for other papers by François Pattou in
Google Scholar
PubMed
Search for other papers by Riyad N H Seervai in
Google Scholar
PubMed
Search for other papers by Coralie Sido in
Google Scholar
PubMed
Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Biochimie et Génétique Moléculaires, Paris, France
INSERM, U1169, Université Paris Sud, Hôpital Bicêtre, Le Kremlin Bicêtre, France
Search for other papers by Caroline Silve in
Google Scholar
PubMed
INSERM, U1418, CIC-EC, Hôpital Européen Georges Pompidou, Paris, France
Search for other papers by Aurélie Vilfaillot in
Google Scholar
PubMed
Search for other papers by Antoine Tabarin in
Google Scholar
PubMed
Search for other papers by Marie-Christine Vantyghem in
Google Scholar
PubMed
Centre de Référence des Maladies Rares du Calcium et du Phosphore Filière de Santé Maladies Rares OSCAR, Paris, France
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, INSERM, UMRS1138, Paris, France
CNRS, ERL8228, Paris, France
Search for other papers by Pascal Houillier in
Google Scholar
PubMed
Search for other papers by the investigators of the Épi-Hypo study in
Google Scholar
PubMed
Context
Recent guidelines have provided recommendations for the care of patients with chronic hypoparathyroidism. Very little is known about actual physicians’ practices or their adherence to such guidelines.
Objective
To describe the physicians’ practice patterns and their compliance with international guidelines.
Design
The cohort studies included were Épi-Hypo (118 physicians and 107 patients, from September 2016 to December 2019) and ePatients (110 patients, November 2019).
Methods
Internet-based cohorts involving all settings at a nationwide level (France). Participants were (i) physicians treating patients with chronic hypoparathyroidism and patients with chronic hypoparathyroidism either participating in the (ii) Épi-Hypo study (Épi-Hypo 2019 patients), or (iii) Hypoparathyroidism France, the national representative association (ePatients).
Results
The physicians’ specialties were mainly endocrinology (61%), nephrology (28%), family medicine (2.5%), pediatrics (2.5%), rheumatology (2%), or miscellaneous (4%) and 45% were practicing in public universities. The median number of pharmaceutical drug classes prescribed was three per patient. The combination of active vitamin D and calcium salt was given to 59 and 58% of ePatients and Épi-Hypo 2019 patients, respectively. Eighty-five percent of ePatients and 87% of physicians reported monitoring plasma calcium concentrations at a steady state at least twice a year. In 32 and 26% of cases, respectively, ePatients and physicians reported being fully in accordance with international guidelines that recommend targeting symptoms, plasma calcium and phosphate values, and urine calcium excretion.
Conclusions
The care of patients with chronic hypoparathyroidism involves physicians with very different practices, so guidelines should include and target other specialists as well as endocrinologists. Full adherence to the guidelines is low in France.
Search for other papers by Glenville Jones in
Google Scholar
PubMed
Vitamin D has many physiological functions including upregulation of intestinal calcium and phosphate absorption, mobilization of bone resorption, renal reabsorption of calcium as well as actions on a variety of pleiotropic functions. It is believed that many of the hormonal effects of vitamin D involve a 1,25-dihydroxyvitamin D3-vitamin D receptor-mediated transcriptional mechanism involving binding to the cellular chromatin and regulating hundreds of genes in many tissues. This comprehensive historical review provides a unique perspective of the many steps of the discovery of vitamin D and its deficiency disease, rickets, stretching from 1650 until the present. The overview is divided into four distinct historical phases which cover the major developments in the field and in the process highlighting the: (a) first recognition of rickets or vitamin D deficiency; (b) discovery of the nutritional factor, vitamin D and its chemical structure; (c) elucidation of vitamin D metabolites including the hormonal form, 1,25-dihydroxyvitamin D3; (d) delineation of the vitamin D cellular machinery, functions and vitamin D-related diseases which focused on understanding the mechanism of action of vitamin D in its many target cells.
Search for other papers by Christian Trummer in
Google Scholar
PubMed
Search for other papers by Stefan Pilz in
Google Scholar
PubMed
Search for other papers by Verena Schwetz in
Google Scholar
PubMed
Search for other papers by Barbara Obermayer-Pietsch in
Google Scholar
PubMed
Search for other papers by Elisabeth Lerchbaum in
Google Scholar
PubMed
Background
Accumulating evidence from animal and human studies suggests that vitamin D is involved in many functions of the reproductive system in both genders.
Aim
The aim of this review was to provide an overview on the effects of vitamin D on polycystic ovary syndrome (PCOS) in women and androgen metabolism in men.
Methods
We performed a systematic literature search in PubMed for relevant English language publications published from January 2012 until September 2017.
Results and discussion
The vitamin D receptor and vitamin D-metabolizing enzymes are found in reproductive tissues of women and men. In women, vitamin D status has been associated with several features of PCOS. In detail, cross-sectional data suggest a regulatory role of vitamin D in PCOS-related aspects such as ovulatory dysfunction, insulin resistance as well as hyperandrogenism. Moreover, results from randomized controlled trials (RCTs) suggest that vitamin D supplementation may be beneficial for metabolic, endocrine and fertility aspects in PCOS. In men, vitamin D status has been associated with androgen levels and hypogonadism. Further, there is some evidence for a favorable effect of vitamin D supplementation on testosterone concentrations, although others failed to show a significant effect on testosterone levels.
Conclusion
In summary, vitamin D deficiency is associated with adverse fertility outcomes including PCOS and hypogonadism, but the evidence is insufficient to establish causality. High-quality RCTs are needed to further evaluate the effects of vitamin D supplementation in PCOS women as well as on androgen levels in men.
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Search for other papers by Agnès Linglart in
Google Scholar
PubMed
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Search for other papers by Martin Biosse-Duplan in
Google Scholar
PubMed
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Search for other papers by Karine Briot in
Google Scholar
PubMed
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Search for other papers by Catherine Chaussain in
Google Scholar
PubMed
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Search for other papers by Laure Esterle in
Google Scholar
PubMed
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Search for other papers by Séverine Guillaume-Czitrom in
Google Scholar
PubMed
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Search for other papers by Peter Kamenicky in
Google Scholar
PubMed
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Search for other papers by Jerome Nevoux in
Google Scholar
PubMed
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Search for other papers by Dominique Prié in
Google Scholar
PubMed
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Search for other papers by Anya Rothenbuhler in
Google Scholar
PubMed
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Service d'Endocrinologie et Diabétologie de l'Enfant, Service de Pédiatrie générale – Consultation de rhumatologie, Service d'Endocrinologie et des Maladies de la Reproduction, Service d'ORL et chirurgie cervico-maxillo-faciale, Université Paris 11, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphore, Service d'Odontologie-Maladies Rares Hôpital Bretonneau 2 rue Carpeaux, Université Paris Descartes 12 Rue de l'École de Médecine, Service Rhumatologie B Hôpital Cochin, Centre de Référence des Maladies Rares des Maladies Auto-Inflammatoires Rares de l'Enfant, Service d'explorations fonctionnelles rénales, Service de Chirurgie infantile orthopédique, Association de patients RVRH-XLH, Hôpital Bicêtre, APHP, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France
Search for other papers by Philippe Wicart in
Google Scholar
PubMed
Search for other papers by Pol Harvengt in
Google Scholar
PubMed
In children, hypophosphatemic rickets (HR) is revealed by delayed walking, waddling gait, leg bowing, enlarged cartilages, bone pain, craniostenosis, spontaneous dental abscesses, and growth failure. If undiagnosed during childhood, patients with hypophosphatemia present with bone and/or joint pain, fractures, mineralization defects such as osteomalacia, entesopathy, severe dental anomalies, hearing loss, and fatigue. Healing rickets is the initial endpoint of treatment in children. Therapy aims at counteracting consequences of FGF23 excess, i.e. oral phosphorus supplementation with multiple daily intakes to compensate for renal phosphate wasting and active vitamin D analogs (alfacalcidol or calcitriol) to counter the 1,25-diOH-vitamin D deficiency. Corrective surgeries for residual leg bowing at the end of growth are occasionally performed. In absence of consensus regarding indications of the treatment in adults, it is generally accepted that medical treatment should be reinitiated (or maintained) in symptomatic patients to reduce pain, which may be due to bone microfractures and/or osteomalacia. In addition to the conventional treatment, optimal care of symptomatic patients requires pharmacological and non-pharmacological management of pain and joint stiffness, through appropriated rehabilitation. Much attention should be given to the dental and periodontal manifestations of HR. Besides vitamin D analogs and phosphate supplements that improve tooth mineralization, rigorous oral hygiene, active endodontic treatment of root abscesses and preventive protection of teeth surfaces are recommended. Current outcomes of this therapy are still not optimal, and therapies targeting the pathophysiology of the disease, i.e. FGF23 excess, are desirable. In this review, medical, dental, surgical, and contributions of various expertises to the treatment of HR are described, with an effort to highlight the importance of coordinated care.
Search for other papers by Barbara J Boucher in
Google Scholar
PubMed
Our knowledge of vitamin D has come a long way since the 100 years it took for doctors to accept, between 1860 and 1890, that both sunlight and cod liver oil (a well-known folk remedy) cured and prevented rickets. Vitamins D2/D3 were discovered exactly a hundred years ago, and over the last 50 years vitamin D has been found to have many effects on virtually all human tissues and not just on bone health, while mechanisms affecting the actions of vitamin D at the cellular level are increasingly understood, but deficiency persists globally. Observational studies in humans have shown that better provision of vitamin D is strongly associated, dose-wise, with reductions in current and future health risks in line with the known actions of vitamin D. Randomised controlled trials, commonly accepted as providing a ‘gold standard’ for assessing the efficacy of new forms of treatment, have frequently failed to provide supportive evidence for the expected health benefits of supplementation. Such RCTs, however, have used designs evolved for testing drugs while vitamin D is a nutrient; the appreciation of this difference is critical to identifying health benefits from existing RCT data and for improving future RCT design. This report aims, therefore, to provide a brief overview of the evidence for a range of non-bony health benefits of vitamin D repletion; to discuss specific aspects of vitamin D biology that can confound RCT design and how to allow for them.
Search for other papers by Johanna Öberg in
Google Scholar
PubMed
Search for other papers by Rolf Jorde in
Google Scholar
PubMed
Diagnostic Clinic, University Hospital of North Norway, Tromso, Norway
Search for other papers by Yngve Figenschau in
Google Scholar
PubMed
Search for other papers by Per Medbøe Thorsby in
Google Scholar
PubMed
Search for other papers by Sandra Rinne Dahl in
Google Scholar
PubMed
Search for other papers by Anne Winther in
Google Scholar
PubMed
Division of Internal Medicine, University Hospital of North Norway, Tromso, Norway
Search for other papers by Guri Grimnes in
Google Scholar
PubMed
Objective
Combined hormonal contraceptive (CHC) use has been associated with higher total 25-hydroxyvitamin D (25(OH)D) levels. Here, we investigate the relation between CHC use and vitamin D metabolism to elucidate its clinical interpretation.
Methods
The cross-sectional Fit Futures 1 included 1038 adolescents. Here, a subgroup of 182 girls with available 25(OH)D, 1,25-dihydroxyvitamin D (1,25(OH)2D), 24,25-dihydroxyvitamin D (24,25(OH)2D), vitamin D-binding protein (DBP) and measured free 25(OH)D levels, in addition to parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), was investigated. Vitamin D metabolites were compared between girls using (CHC+) and not using CHC (CHC−). Further, the predictability of CHC on 25(OH)D levels was assessed in a multiple regression model including lifestyle factors. The ratios 1,25(OH)2D/25(OH)D and 24,25(OH)2D/25(OH)D (vitamin D metabolite ratio (VMR)) in relation to 25(OH)D were presented in scatterplots.
Results
CHC+ (n = 64; 35% of the girls) had higher 25(OH)D levels (mean ± s.d., 60.3 ± 22.2) nmol/L) than CHC- (n = 118; 41.8 ± 19.3 nmol/L), P -values <0.01. The differences in 25(OH)D levels between CHC+ and CHC− were attenuated but remained significant after the adjustment of lifestyle factors. CHC+ also had higher levels of 1,25(OH)2D, 24,25(OH)2D, DBP and calcium than CHC−, whereas 1,25(OH)2D/25(OH)D, PTH, FGF23 and albumin were significantly lower. Free 25(OH)D and VMR did not statistically differ, and both ratios appeared similar in relation to 25(OH)D, irrespective of CHC status.
Conclusion
This confirms a clinical impact of CHC on vitamin D levels in adolescents. Our observations are likely due to an increased DBP-concentration, whereas the free 25(OH)D appears unaltered.
Search for other papers by Julia Kubiak in
Google Scholar
PubMed
Search for other papers by Per Medbøe Thorsby in
Google Scholar
PubMed
Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
Search for other papers by Elena Kamycheva in
Google Scholar
PubMed
Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
Search for other papers by Rolf Jorde in
Google Scholar
PubMed
Objective
Low serum 25(OH)D levels are associated with cardiovascular disease (CVD) and some of its risk factors. However, in interventional studies, the effects of vitamin D supplementation have been uncertain, possibly due to inclusion of vitamin D-sufficient subjects. Our aim was therefore to examine effects of vitamin D supplementation on CVD risk factors in vitamin D-insufficient subjects.
Design
Double-blinded randomized controlled trial.
Methods
A 4-month interventional study with high-dose vitamin D (100,000 IU loading dose, followed by 20,000 IU/week) or placebo with measurements of blood pressure, lipids (total-, LDL- and HDL-cholesterol, triglycerides, apolipoproteins A1 and B), and glucose metabolism parameters (blood glucose, HbA1c, serum human receptors for advanced glycation end products (sRAGE), insulin, C-peptide and HOMA-IR).
Results
A total of 422 subjects with mean serum 25(OH)D level 34 nmol/L were included, with 411 subjects completing the study. Serum 25(OH)D levels increased with 56 nmol/L and decreased with 4 nmol/L in the vitamin D and placebo group, respectively. We found no statistically significant differences between the two groups in any of the measured CVD risk factors, except for a minor increase in sRAGE in the vitamin D group. Stratified analyses of subjects with low baseline serum 25(OH)D levels alone, or combined with blood pressure, lipid and HOMA-IR values above the median for the cohort, did not skew the results in favour of vitamin D supplementation.
Conclusion
Supplementation with vitamin D in subjects with baseline vitamin D insufficiency does not improve CVD risk factor profile.
Search for other papers by Raja Padidela in
Google Scholar
PubMed
Search for other papers by Moira S Cheung in
Google Scholar
PubMed
Search for other papers by Vrinda Saraff in
Google Scholar
PubMed
Search for other papers by Poonam Dharmaraj in
Google Scholar
PubMed
X-linked hypophosphataemia (XLH) is caused by a pathogenic variant in the PHEX gene, which leads to elevated circulating FGF23. High FGF23 causes hypophosphataemia, reduced active vitamin D concentration and clinically manifests as rickets in children and osteomalacia in children and adults. Conventional therapy for XLH includes oral phosphate and active vitamin D analogues but does not specifically treat the underlying pathophysiology of elevated FGF23-induced hypophosphataemia. In addition, adherence to conventional therapy is limited by frequent daily dosing and side effects such as gastrointestinal symptoms, secondary hyperparathyroidism and nephrocalcinosis. Burosumab, a recombinant human IgG1 MAB that binds to and inhibits the activity of FGF23, is administered subcutaneously every 2 weeks. In clinical trials (phase 2 and 3) burosumab was shown to improve phosphate homeostasis that consequently resolves the skeletal/non-skeletal manifestations of XLH. Burosumab was licensed in Europe (February 2018) with the National Institute for Health and Care Excellence, UK approving use within its marketing authorisation in October 2018. In this publication, the British Paediatric and Adolescent Bone Group (BPABG) reviewed current evidence and provide expert recommendations for care pathway and management of XLH with burosumab.
Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
Search for other papers by Rolf Jorde in
Google Scholar
PubMed
Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
Search for other papers by Guri Grimnes in
Google Scholar
PubMed
Objective
In addition to its skeletal effects, vitamin D may also be important for health in general. It is uncertain what level of serum 25-hydroxyvitamin D (25(OH)D), marker of vitamin D status, is sufficient for these effects. With decreasing serum 25(OH)D levels there is an increase in serum PTH. The point at which this occurs has been considered as a threshold for vitamin D sufficiency. The thresholds found have varied widely and have mainly been based on observational studies. However, to truly establish a threshold for vitamin D effects, this has to be based on randomized controlled trials (RCTs).
Methods
The study included 2803 subjects from a general health survey, the Tromsø study, and pooled individual person data from five vitamin D intervention studies (n = 1544). Serum parathyroid hormone (PTH) and change in PTH after vitamin D supplementation were related to serum 25(OH)D levels in steps of 25 nmol/L (<24, 25–49, 50–74, 75–99, and >99 nmol/L).
Results
In the Tromsø study, in the females there was a gradual decrease in serum PTH with increasing serum 25(OH)D with no apparent plateau, whereas in the males the decrease in PTH in subjects with serum 25(OH)D >74 nmol/l was marginal. In pooled RCTs, there was a significant reduction in serum PTH by vitamin D supplementation regardless of baseline serum 25(OH)D level.
Conclusions
The use of the serum PTH–25(OH)D relation from observational studies to determine a threshold for vitamin D sufficiency is highly questionable.
Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Search for other papers by K Amrein in
Google Scholar
PubMed
Search for other papers by A Papinutti in
Google Scholar
PubMed
Department of General Surgery, St. Elisabeth’s Hospital, Graz, Austria
Search for other papers by E Mathew in
Google Scholar
PubMed
Search for other papers by G Vila in
Google Scholar
PubMed
Search for other papers by D Parekh in
Google Scholar
PubMed
The prevalence of vitamin D deficiency in intensive care units ranges typically between 40 and 70%. There are many reasons for being or becoming deficient in the ICU. Hepatic, parathyroid and renal dysfunction additionally increases the risk for developing vitamin D deficiency. Moreover, therapeutic interventions like fluid resuscitation, dialysis, surgery, extracorporeal membrane oxygenation, cardiopulmonary bypass and plasma exchange may significantly reduce vitamin D levels. Many observational studies have consistently shown an association between low vitamin D levels and poor clinical outcomes in critically ill adults and children, including excess mortality and morbidity such as acute kidney injury, acute respiratory failure, duration of mechanical ventilation and sepsis. It is biologically plausible that vitamin D deficiency is an important and modifiable contributor to poor prognosis during and after critical illness. Although vitamin D supplementation is inexpensive, simple and has an excellent safety profile, testing for and treating vitamin D deficiency is currently not routinely performed. Overall, less than 800 patients have been included in RCTs worldwide, but the available data suggest that high-dose vitamin D supplementation could be beneficial. Two large RCTs in Europe and the United States, together aiming to recruit >5000 patients, have started in 2017, and will greatly improve our knowledge in this field. This review aims to summarize current knowledge in this interdisciplinary topic and give an outlook on its highly dynamic future.
